LILRB2 (IO-108 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is a research-grade biosimilar to IO-108, designed to target LILRB2 (Leukocyte Immunoglobulin-Like Receptor B2), also known as ILT4 or CD85d. LILRB2 is an inhibitory receptor predominantly expressed on myeloid cells, including monocytes, macrophages, and dendritic cells, where it functions to suppress immune responses by recognizing MHC class I molecules and other ligands. Upon engagement, LILRB2 delivers immunosuppressive signals through ITIM domains in its cytoplasmic tail, dampening inflammatory responses and antigen presentation. This receptor plays a critical role in maintaining immune homeostasis but is frequently exploited by tumors to create an immunosuppressive microenvironment, making it a relevant target in cancer immunology research, particularly in acute myeloid leukemia, solid tumors, and immune evasion mechanisms.

IO-108 represents a therapeutic antibody developed to block LILRB2-mediated immunosuppression and restore anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating LILRB2 biology, studying myeloid cell regulation, exploring checkpoint mechanisms in the tumor microenvironment, and evaluating potential immunotherapeutic strategies targeting myeloid-mediated immune suppression.